Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10488MR)

This product GTTS-WQ10488MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10488MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14389MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ9666MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ710MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ4949MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ4210MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ486MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ1822MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ2965MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANB020
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.